12486 Federal Register / Vol. 80, No. 45 / Monday, March 9, 2015 / Notices 

H. Should any provision of these 

Official Rules be or become illegal or 

unenforceable under applicable Federal 

law, such illegality or unenforceability 

shall leave the remainder of these 

Official Rules unaffected and valid. The 

illegal or unenforceable provision may 

be replaced by the Sponsor with a valid 

and enforceable provision that, in the 

Sponsor’s sole judgment, comes closest 

and best reflects the Sponsor’s intention 

in a legal and enforceable manner with 

respect to the invalid or unenforceable 

provision. 

13. Disputes 

Subject to the release provisions in 

these Official Rules, Contestant agrees 

that: 

A. Any and all disputes, claims, and 

causes of action arising out of or 

connected with this Contest, any Prizes 

awarded, the administration of the 

Contest, the determination of Winners, 

or the construction, validity, 

interpretation, and enforceability of the 

Official Rules shall be resolved 

individually; 

B. any and all disputes, claims, and 

causes of action arising out of or 

connected with this Contest, any Prizes 

awarded, the administration of the 

Contest, the determination of Winners, 

or the construction, validity, 

interpretation, and enforceability of the 

Official Rules shall be resolved pursuant 

to Federal law; 

C. under no circumstances will 

Contestants be entitled to, and 

Contestants hereby waive, all rights to 

claim, any punitive, incidental, and 

consequential damages and any and all 

rights to have damages multiplied or 

otherwise increased. 

14. Privacy 

The Sponsor may collect personal 

information from the Contestant when 

he or she enters the Contest. Such 

personal information collected is subject 

to the privacy policy located here: 

http://www.ftc.gov/site-information/

privacy-policy. 

15. Contact Us 

Please visit the Contest Web site for 

further Contest information and 

updates. 

Jessica Rich, 

Director, Bureau of Consumer Protection. 

[FR Doc. 2015–05442 Filed 3–6–15; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0510] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Substances 

Prohibited From Use in Animal Food or 

Feed 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Fax written comments on the 

collection of information by April 8, 

2015. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–7285, or emailed to oira_

submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number 0910–0627. Also 

include the FDA docket number found 

in brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: FDA 

PRA Staff, Office of Operations, Food 

and Drug Administration, 8455 

Colesville Rd.; COLE–14526, Silver 

Spring, MD 20993–0002 PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Substances Prohibited From Use in 

Animal Food or Feed—21 CFR Part 589 

(OMB Control Number 0910–0627— 

Revision) 

This regulation prohibits the use of 

certain cattle origin materials in the 

food or feed of all animals to help 

prevent the spread of bovine spongiform 

encephalopathy (BSE) in U.S. cattle. 

BSE is a progressive and fatal 

neurological disorder of cattle that 

results from an unconventional 

transmissible agent. BSE belongs to the 

family of diseases known as 

transmissible spongiform 

encephalopathies (TSEs). All TSEs 

affect the central nervous system of 

infected animals. These measures will 

further strengthen existing safeguards 

against BSE. 

In the Federal Register of November 

21, 2014 (79 FR 69493), FDA published 

a 60-day notice requesting public 

comment on the proposed collection of 

information. One comment was received 

however it did not respond to any of the 

four information collection topics 

solicited and is therefore not addressed 

by the Agency. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1

21 CFR Section 589.2001; 

Substances prohibited from use in 

animal food or feed 

Number of 

recordkeepers 

Number of 

records per 

recordkeeper 

Total annual 

records 

Average 

burden per 

recordkeeper 

Total hours 

Operating and 

maintenance 

costs 

589.2001(c)(2)(vi) and (c)(3)(i) ................ 175 1 175 20 3,500 $59,500 

589.2001(c)(2)(ii) ...................................... 50 1 50 20 1,000 17,000 

589.2001(c)(3)(i)(A) .................................. 175 1 175 26 4,550 80,580 

Total .................................................. ........................ ........................ ........................ ........................ 9,050 157,080 

1There are no capital costs associated with this collection of information. 

Description of Respondents for 

Recordkeeping: Rendering facilities, 

medicated feed manufacturers, livestock 

feeders. 

The Agency’s recordkeeping burden 

estimate was calculated by multiplying 

the number of recordkeepers times the 

number of records per recordkeeper to 

determine the total annual number of 

records. The total number of annual 

records were then multiplied by the 

average burden per recordkeeper to 

determine the total number of burden 

hours. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 80, No. 45 / Monday, March 9, 2015 / Notices 12487 

TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1

21 CFR section 589.2001(f) Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average 

burden per 

respondent 

Total hours 

One-time (initial) burden ...................................................... 1 1 1 80 80 

Burden from future review ................................................... 1 1 1 26 26 

1There are no capital costs or operating costs associated with the collection of information. 

Description of Respondents for 

Reporting: The final regulation on BSE 

(73 FR 22720) included a provision that 

exempts cattle materials prohibited in 

animal feed (CMPAF) from designated 

countries from the prohibition on its use 

in animal feed. A foreign country 

seeking this designation will submit a 

written request to FDA that includes a 

variety of information about the 

country’s BSE status (§ 589.2001(f)). 

During the past 6 years, FDA received 

2 requests from countries to be 

exempted from CMPAF restrictions. 

One-Time (Initial) Reporting Burden 

There is a one-time burden to 

countries that apply to FDA seeking to 

be designated as not subject to 

restrictions applicable to CMPAF. We 

estimate that each country that applies 

for an exclusion will spend 80 hours 

putting information together to submit 

to FDA. Table 2 row 1 presents the onetime burden for the exclusion. (See final 

BSE regulation at 73 FR 22754). 

Recurring Burden 

Countries that successfully petition 

FDA to be designated as exempt from 

certain BSE-related restrictions 

applicable to animal feed will be subject 

to future review by FDA to ensure that 

their designation remains appropriate. 

As part of this process, FDA may ask 

designated countries from time-to-time 

to confirm that their BSE situation and 

the information submitted by them in 

support of their original application 

remains unchanged. We assume it will 

take FDA and the designated country 

undergoing a review in the future about 

one third the time and effort it did when 

the information was submitted. Table 2 

row 2 presents the expected recurring 

burden. 

Dated: March 2, 2015. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2015–05356 Filed 3–6–15; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel Small Business Innovation 

Research (SBIR). 

Date: March 31, 2015. 

Time: 8:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Rahat Khan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Center for Advancing 

Translational Sciences, 6701 Democracy 

Blvd., Rm 1078, Bethesda, MD 20892, 301– 

894–7319, khanr2@csr.nih.gov. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel CTSA Meeting 1. 

Date: April 8–9, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Carol Lambert, Ph.D., 

Acting Deputy Director, Office of Grants 

Management & Scientific Review, National 

Center for Advancing Translational Sciences 

(NCATS) National Institutes of Health, 6701 

Democracy Boulevard, Democracy 1, Room 

1076, Bethesda, MD 20892, 301–435–0814, 

lambert@mail.nih.gov. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel 2015 CTSA Application 

Review. 

Date: April 15–16, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Guo He Zhang, Ph.D., 

MPH, Scientific Review Office, Office of 

Grants Management & Scientific Review, 

National Center for Advancing Translational 

Sciences (NCATS) National Institutes of 

Health, 6701 Democracy Boulevard, 

Democracy 1, Room 1064, Bethesda, MD 

20892, 301–435–0812, zhanggu@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B–Cooperative Agreements; 

93.859, Biomedical Research and Research 

Training, National Institutes of Health, HHS). 

Dated: March 3, 2015. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–05304 Filed 3–6–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request Surveys and 

Interviews To Support an Evaluation of 

the Innovative Molecular Analysis 

Technologies (IMAT) Program (NCI) 

SUMMARY: Under the provisions of 

section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH), has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. This proposed information 

collection was previously published in 

the Federal Register on December 4, 

2014, Vol. 79, Page 72004 and allowed 

60-days for public comment. No public 

comments were received. The purpose 

of this notice is to allow an additional 

30 days for public comment. The 

National Cancer Institute (NCI), 

National Institutes of Health, may not 

conduct or sponsor, and the respondent 

is not required to respond to, an 

mstockstill on DSK4VPTVN1PROD with NOTICES